FDA alert: Low survival with Keytruda, Tecentriq in urothelial cancer

FDA issued an alert to healthcare professionals and cancer clinical investigators warning about decreased survival associated with

Read the full 177 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE